Home › Acute Myeloid Leukemia › NCT05909501

Assessment of Geriatric Evaluations Impact on New AML Guidance

AGE-ING (Assessment of Geriatric Evaluations Impact on New AML Guidance) Study

Who can join

Ages 50 and older · All sexes

Inclusion Criteria:

* AML diagnosis by peripheral flow cytometry and/or bone marrow aspirate and biopsy
* New diagnosis being considered for new line of treatment
* Age ≥ 50 years.
* Performance status 0,1, and 2

Exclusion Criteria:

* Inability to understand or unable to sign a written informed consent
* Unable to fill out questionnaires on their own and/or do not have someone to help complete them

About the study

The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.

Sponsor: Abramson Cancer Center at Penn Medicine · Participants: 100 · Started: Oct 25, 2023

Contact the study team

• Colleen Redlinger · Phone: 2152209693
• Catherine Lai, MD · Phone: 2153600561

Official record on ClinicalTrials.gov — NCT05909501

Locations in the U.S.

Conditions

• Acute Myeloid Leukemia

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.